Durable complete response after a single cycle of pembrolizumab-based chemoimmunotherapy in metastatic squamous cell lung cancer: a case report
Discover Oncology · 08.08.2026 · 17 (1)
DOI: 10.1007/s12672-026-05641-6 ↗Kurz gefasst
Fallbericht in der Zeitschrift Discover Oncology, online erschienen am 08.08.2026. Verfasst von Simay Çokgezer und 1 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Squamous cell lung cancer (SqCLC) is an aggressive subtype of non-small cell lung cancer (NSCLC), frequently associated with distant metastases. Although immune checkpoint inhibitors improve survival, complete responses after a single cycle of pembrolizumab-based chemoimmunotherapy are exceedingly rare. A 77-year-old Turkish male with hypertension and type 2 diabetes presented with acute left arm weakness. He was a never-smoker with a history of urothelial carcinoma. Brain MRI revealed right paracentral and cerebellar metastatic lesions, while thoracic imaging showed multiple pulmonary nodules. Histopathology confirmed metastatic SqCLC with a PD-L1 tumor proportion score of 40%. The patient underwent craniotomy and stereotactic radiosurgery, followed by one cycle of gemcitabine, carboplatin, and pembrolizumab. Treatment-related toxicities (grade 2 fatigue, neutropenia, mild infection, and grade 1 skin toxicity) resolved with supportive care. Despite clinical stability, the patient declined further therapy. Follow-up imaging demonstrated complete resolution of all lesions. At 24 months, he remains in complete remission. This case illustrates a rare, durable complete response—including intracranial disease—after a single cycle of pembrolizumab-based chemoimmunotherapy in metastatic SqCLC.
Zitieren
APA
Çokgezer, S., & Ak, N. (2026). Durable complete response after a single cycle of pembrolizumab-based chemoimmunotherapy in metastatic squamous cell lung cancer: a case report. Discover Oncology, 17(1). https://doi.org/10.1007/s12672-026-05641-6
Vancouver
Çokgezer S, Ak N. Durable complete response after a single cycle of pembrolizumab-based chemoimmunotherapy in metastatic squamous cell lung cancer: a case report. Discover Oncology. 2026;17(1). doi:10.1007/s12672-026-05641-6
BibTeX
@article{okgezer2026,
author = {Çokgezer, Simay and Ak, Naziye},
title = {Durable complete response after a single cycle of pembrolizumab-based chemoimmunotherapy in metastatic squamous cell lung cancer: a case report},
journal = {Discover Oncology},
year = {2026},
volume = {17},
number = {1},
doi = {10.1007/s12672-026-05641-6}
}
EUVIMED